Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 64.04 CNY -4.28% Market Closed
Market Cap: 17B CNY
Have any thoughts about
Suzhou Zelgen Biopharmaceuticals Co Ltd?
Write Note

Suzhou Zelgen Biopharmaceuticals Co Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Suzhou Zelgen Biopharmaceuticals Co Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Short-Term Investments
ÂĄ137m
CAGR 3-Years
-33%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Short-Term Investments
ÂĄ7.5B
CAGR 3-Years
-32%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Short-Term Investments
ÂĄ2.5B
CAGR 3-Years
188%
CAGR 5-Years
506%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Short-Term Investments
ÂĄ1.5B
CAGR 3-Years
87%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Short-Term Investments
ÂĄ1.5B
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Suzhou Zelgen Biopharmaceuticals Co Ltd
Glance View

Market Cap
17B CNY
Industry
Biotechnology

Suzhou Zelgen Biopharmaceuticals Co., Ltd. engages in the innovation, research, development, manufacturing, and commercialization of new medications. The company is headquartered in Suzhou, Jiangsu and currently employs 688 full-time employees. The company went IPO on 2020-01-23. The firm's main technology platforms include precision small molecule drugs R & D and industrialization platform and complex recombinant protein drug development and industrialization platform. The firm's R & D product pipelines include Donafenib, Recombinant human thrombin for topical use, Jaktinib hydrochloride tablets, Alkotinib, Recombinant human thyroid stimulating hormone for injection, Jaktinib hydrochloride cream, ZG5266, ZG0588, ZG170607, double Specific antibodies ZG005 and ZG006. The firm also provides R & D and clinical trial drug production and processing services. The firm operates its businesses primarily in Mainland China.

Intrinsic Value
57.58 CNY
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Short-Term Investments?
Short-Term Investments
137m CNY

Based on the financial report for Dec 31, 2023, Suzhou Zelgen Biopharmaceuticals Co Ltd's Short-Term Investments amounts to 137m CNY.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
11%

Over the last year, the Short-Term Investments growth was -45%. The average annual Short-Term Investments growth rates for Suzhou Zelgen Biopharmaceuticals Co Ltd have been -33% over the past three years , 11% over the past five years .

Back to Top